JP5770161B2 - 血小板への第ｖｉｉｉ因子タンパク質の標的送達 - Google Patents

血小板への第ｖｉｉｉ因子タンパク質の標的送達 Download PDF

Info

Publication number
JP5770161B2
JP5770161B2 JP2012503990A JP2012503990A JP5770161B2 JP 5770161 B2 JP5770161 B2 JP 5770161B2 JP 2012503990 A JP2012503990 A JP 2012503990A JP 2012503990 A JP2012503990 A JP 2012503990A JP 5770161 B2 JP5770161 B2 JP 5770161B2
Authority
JP
Japan
Prior art keywords
fviii
buffer
nacl
protein
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012503990A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012522529A5 (https=
JP2012522529A (ja
Inventor
ヘンリク・ウスタゴー
トニー・プサテリ
トーマス・アール・バーネット
イェンス・ブヒアルト
ベルント・ペシュケ
ミケール・コフォーズ−ハンセン
マガリ・ア・ズンデル
カルステン・ベーレンス
エヴァ・ホ・ノーリング・オルセン
ヘニング・ステンニケ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42238764&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5770161(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2012522529A publication Critical patent/JP2012522529A/ja
Publication of JP2012522529A5 publication Critical patent/JP2012522529A5/ja
Application granted granted Critical
Publication of JP5770161B2 publication Critical patent/JP5770161B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2012503990A 2009-04-06 2010-04-06 血小板への第ｖｉｉｉ因子タンパク質の標的送達 Expired - Fee Related JP5770161B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21200409P 2009-04-06 2009-04-06
US61/212,004 2009-04-06
US18607509P 2009-06-11 2009-06-11
US61/186,075 2009-06-11
PCT/EP2010/054495 WO2010115866A1 (en) 2009-04-06 2010-04-06 Targeted delivery of factor viii proteins to platelets

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015125394A Division JP2015166391A (ja) 2009-04-06 2015-06-23 血小板への第ｖｉｉｉ因子タンパク質の標的送達

Publications (3)

Publication Number Publication Date
JP2012522529A JP2012522529A (ja) 2012-09-27
JP2012522529A5 JP2012522529A5 (https=) 2013-04-25
JP5770161B2 true JP5770161B2 (ja) 2015-08-26

Family

ID=42238764

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012503990A Expired - Fee Related JP5770161B2 (ja) 2009-04-06 2010-04-06 血小板への第ｖｉｉｉ因子タンパク質の標的送達
JP2015125394A Pending JP2015166391A (ja) 2009-04-06 2015-06-23 血小板への第ｖｉｉｉ因子タンパク質の標的送達

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015125394A Pending JP2015166391A (ja) 2009-04-06 2015-06-23 血小板への第ｖｉｉｉ因子タンパク質の標的送達

Country Status (6)

Country Link
US (2) US20120093840A1 (https=)
EP (1) EP2417155B1 (https=)
JP (2) JP5770161B2 (https=)
CN (1) CN102482340B (https=)
ES (1) ES2427627T3 (https=)
WO (1) WO2010115866A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015166391A (ja) * 2009-04-06 2015-09-24 ノヴォ ノルディスク アー／エス 血小板への第ｖｉｉｉ因子タンパク質の標的送達

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
PL2257311T3 (pl) * 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
CN102112144A (zh) * 2008-05-16 2011-06-29 拜耳医药保健有限公司 靶向性凝固因子及其使用方法
CN102812039B (zh) 2010-02-16 2016-01-20 诺沃—诺迪斯克有限公司 缀合蛋白质
EP2536753B1 (en) * 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
TW201217527A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
WO2012117091A1 (en) 2011-03-02 2012-09-07 Novo Nordisk A/S Coagulation factor-targeting to tlt-1 on activated platelets
CA2875247A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
WO2013185113A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
EP2897634B1 (en) * 2012-09-12 2018-03-21 Centre for Bioseparation Technology-VIT Double mutant coagulation factor viii and methods thereof
CN104661685A (zh) 2012-10-15 2015-05-27 诺和诺德保健Ag（股份有限公司） 因子vii缀合物
HK1214539A1 (zh) 2012-10-30 2016-07-29 Bioverativ Therapeutics Inc. 應用viii因子多肽的方法
WO2014127215A1 (en) * 2013-02-15 2014-08-21 Biogen Idec Ma Inc. Optimized factor viii gene
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
EP4122487A1 (en) * 2013-03-15 2023-01-25 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations
US10364288B2 (en) 2013-05-24 2019-07-30 Biogen Ma Inc. Anti-GPIIB/IIIA antibodies or uses thereof
CA2927756A1 (en) 2013-10-15 2015-04-23 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
RU2695428C2 (ru) * 2014-01-20 2019-07-23 Октафарма Аг СПОСОБ ПРОИЗВОДСТВА ФАКТОРА VIII, ИМЕЮЩЕГО УЛУЧШЕННОЕ СООТНОШЕНИЕ FVIII:C/FVIII:Ag
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
CN106687126B (zh) 2014-08-04 2020-07-28 杰特有限公司 因子viii制剂
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
ES2772933T3 (es) 2015-03-06 2020-07-08 CSL Behring Lengnau AG Factor de von Willebrand modificado que tiene una semivida mejorada
JP2018533017A (ja) * 2015-10-02 2018-11-08 ティージーアール バイオサイエンシス ピーティーワイ エルティーディー． 多基体による検体検出
EA202190827A1 (ru) 2015-11-13 2021-11-30 Баксалта Инкорпорейтед Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
CA3012695A1 (en) 2016-02-01 2017-08-10 Bioverativ Therapeutics Inc. Optimized factor viii genes
EP3205665A1 (en) * 2016-02-11 2017-08-16 Octapharma AG Method of separating factor viii from blood products
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
US12091675B2 (en) 2018-07-16 2024-09-17 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
KR20220097891A (ko) 2019-09-30 2022-07-08 바이오버라티브 테라퓨틱스 인크. 렌티바이러스 벡터 제형
US20220348637A1 (en) 2019-11-11 2022-11-03 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
MX2023000156A (es) 2020-06-24 2023-02-16 Bioverativ Therapeutics Inc Metodos para la eliminacion de factor viii libre de preparaciones de vectores lentivirales modificados para expresar dicha proteina.
CN113248594B (zh) * 2021-04-26 2022-08-30 北京美康基免生物科技有限公司 一种重组凝血因子viii及其应用
EP4662240A2 (fr) 2023-02-09 2025-12-17 Commissariat à l'Energie Atomique et aux Energies Alternatives Fragment fab mutant pour l'obtention de conjugués mono- ou bi-fonctionnalisés site-spécifiques

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2645588A (en) * 1987-12-04 1989-06-15 Scripps Clinic And Research Foundation The von willebrand factor binding domain of factor viii
KR940009084B1 (ko) * 1988-05-18 1994-09-29 체크 포인트 시스템스, 인코오퍼레이티드 자기 및 공명회로 검출용 안테나 시스템
JPH0433A (ja) 1990-04-11 1992-01-06 Nissan Motor Co Ltd 粘度可変流体封入制御型エンジンマウント
JPH0434A (ja) 1990-04-13 1992-01-06 Tokai Rubber Ind Ltd 流体封入式筒型マウント装置
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
DE69519929T2 (de) * 1994-07-11 2001-05-23 Board Of Regents, The University Of Texas System Verfahren und zusammensetzungen für die spezifische koagulation von tumorgefässen
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
GB9724143D0 (en) * 1997-11-14 1998-01-14 Andaris Ltd Pharmaceutical conjugate
US20030236190A1 (en) 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
US20090176967A1 (en) 2004-08-02 2009-07-09 Novo Nordisk Healthcare A/G Conjugation of FVII
ES2309785T3 (es) 2004-08-13 2008-12-16 F. Hoffmann-La Roche Ag Modificacion c-terminal de polipeptidos.
EP1871801A2 (en) * 2005-04-01 2008-01-02 Novo Nordisk Health Care AG Blood coagulation fviii analogues
WO2008025856A2 (en) * 2006-09-01 2008-03-06 Novo Nordisk Health Care Ag Modified glycoproteins
CA2673459C (en) * 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
PL2257311T3 (pl) * 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
CN102112144A (zh) * 2008-05-16 2011-06-29 拜耳医药保健有限公司 靶向性凝固因子及其使用方法
ES2427627T3 (es) * 2009-04-06 2013-10-31 Novo Nordisk A/S Entrega dirigida de proteínas de Factor VIII a plaquetas

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015166391A (ja) * 2009-04-06 2015-09-24 ノヴォ ノルディスク アー／エス 血小板への第ｖｉｉｉ因子タンパク質の標的送達

Also Published As

Publication number Publication date
WO2010115866A1 (en) 2010-10-14
EP2417155A1 (en) 2012-02-15
JP2015166391A (ja) 2015-09-24
US20160251409A1 (en) 2016-09-01
EP2417155B1 (en) 2013-06-19
CN102482340A (zh) 2012-05-30
ES2427627T3 (es) 2013-10-31
CN102482340B (zh) 2015-05-13
JP2012522529A (ja) 2012-09-27
US20120093840A1 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
JP5770161B2 (ja) 血小板への第ｖｉｉｉ因子タンパク質の標的送達
DK2298347T3 (en) COAGULATION FACTOR CHEMICAL PROTEINS FOR TREATING A HEMOSTATIC DISORDER
KR101841870B1 (ko) 표적화 응고 인자 및 그의 사용 방법
US20130040888A1 (en) Factor VIII Molecules With Reduced VWF Binding
JP2017190342A (ja) 因子ｖｉｉｉ融合タンパク質
CA2875247A1 (en) Chimeric clotting factors
JP6676551B2 (ja) 改変フォンウィルブランド因子
JP2019522977A (ja) Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用
JP2016525099A (ja) ＦｃＲｎ結合力が維持される免疫グロブリンＦｃ結合体
JP7252890B2 (ja) 血友病を処置するための切断型フォン・ヴィルブランド因子ポリペプチド
KR102785415B1 (ko) 혈전성 질환을 치료하기 위한 가용성 당단백질 v
HK1260028B (en) Soluble glycoprotein v for treating thrombotic diseases
HK1260028A1 (en) Soluble glycoprotein v for treating thrombotic diseases
HK1196565B (en) Blood coagulation factor vii and viia derivatives, conjugates and complexes comprising the same, and use thereof
HK1196565A (en) Blood coagulation factor vii and viia derivatives, conjugates and complexes comprising the same, and use thereof
HK1153929A (en) Targeted coagulation factors and method of using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141031

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150525

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150624

R150 Certificate of patent or registration of utility model

Ref document number: 5770161

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees